GRFS
Grifols, S.A. NASDAQ$8.23
Mkt Cap $7.0B
52w Low $7.08
28.3% of range
52w High $11.14
50d MA $8.29
200d MA $9.19
P/E (TTM)
14.4x
EV/EBITDA
8.2x
P/B
0.7x
Debt/Equity
1.7x
ROE
β
P/FCF
7.2x
RSI (14)
β
ATR (14)
β
Beta
1.21
50d MA
$8.29
200d MA
$9.19
Avg Volume
750.8K
About
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent,β¦
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide β²β |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.29 | 0.29 | -0.3% | 8.96 | -2.9% | +1.6% | +1.5% | -3.6% | -3.3% | -4.1% | β |
| Nov 4, 2025 | AMC | 0.24 | 0.22 | -9.6% | 9.22 | -3.7% | -6.4% | -9.3% | -8.5% | -6.7% | -5.3% | β |
| Jul 28, 2025 | AMC | 0.23 | 0.19 | -17.4% | 10.09 | -0.2% | +4.1% | +7.5% | +6.0% | +6.8% | +6.2% | β |
| May 12, 2025 | AMC | 0.14 | 0.10 | -28.6% | 7.73 | +1.0% | +1.7% | -2.1% | +1.6% | +0.4% | +3.5% | β |
| Mar 6, 2025 | AMC | 0.13 | 0.26 | +100.0% | 8.50 | -0.8% | -0.8% | -8.2% | -9.1% | -8.7% | -9.2% | β |
| Nov 7, 2024 | AMC | 0.22 | 0.16 | -27.3% | 9.50 | +4.8% | -0.1% | -1.9% | -4.2% | -4.3% | +0.5% | β |
| Jul 30, 2024 | AMC | 0.23 | 0.02 | -91.3% | 7.75 | +1.9% | -3.6% | -1.4% | -2.2% | -6.2% | -6.6% | β |
| May 14, 2024 | AMC | 0.15 | 0.07 | -53.3% | 7.47 | +1.5% | +2.9% | +2.7% | +3.1% | +2.8% | +2.7% | β |
| Mar 5, 2024 | AMC | 0.22 | 0.14 | -36.4% | 6.17 | -12.6% | -11.3% | -9.1% | +13.5% | +9.7% | +1.9% | β |
| Nov 2, 2023 | AMC | 0.22 | 0.11 | -50.0% | 9.04 | +1.1% | +3.0% | +1.3% | +0.8% | +1.0% | -0.4% | β |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 8 | JP Morgan | Maintains | Neutral β Neutral | β | $8.85 | $8.91 | +0.7% | +1.5% | -0.3% | +1.1% | +3.5% | +3.3% |
| Jun 17 | JP Morgan | Maintains | Neutral β Neutral | β | $9.09 | $9.07 | -0.2% | -2.4% | -4.3% | -3.5% | -7.9% | -6.1% |
| Mar 12 | Deutsche Bank | Downgrade | Hold β Sell | β | $6.77 | $6.68 | -1.3% | -7.1% | -6.4% | -14.9% | -9.5% | -10.6% |
| Dec 5 | JP Morgan | Maintains | Neutral β Neutral | β | $9.71 | $9.72 | +0.1% | +0.5% | +3.0% | +5.6% | +6.8% | +4.8% |
| Nov 5 | Deutsche Bank | Downgrade | Buy β Hold | β | $12.49 | $12.40 | -0.7% | -2.2% | +0.1% | -1.5% | -1.5% | -3.5% |
| Mar 23 | Credit Suisse | Upgrade | Neutral β Outperform | β | $16.00 | $16.50 | +3.1% | +4.9% | +5.8% | +9.0% | +10.1% | +8.3% |
| Mar 11 | HSBC | Upgrade | Hold β Buy | β | $15.15 | $15.85 | +4.6% | +5.7% | +6.1% | +5.9% | +6.3% | +9.4% |
| Oct 28 | Santander | Upgrade | Hold β Buy | β | $21.01 | $21.03 | +0.1% | +0.7% | +2.9% | +2.8% | +4.3% | +5.2% |
| Jun 27 | JP Morgan | Upgrade | Neutral β Overweight | β | $19.90 | $20.17 | +1.4% | +3.4% | +6.0% | +5.0% | +5.9% | +7.5% |
| Feb 8 | Berenberg | Downgrade | Buy β Hold | β | $19.21 | $18.24 | -5.0% | -6.2% | -5.4% | -2.3% | -1.1% | -0.9% |
Data updated apr 26, 2026 10:45am
Β· Source: massive.com